166 related articles for article (PubMed ID: 15516942)
1. A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children.
González-Vicent M; Madero L; Sevilla J; Ramirez M; Díaz MA
Bone Marrow Transplant; 2004 Dec; 34(12):1077-81. PubMed ID: 15516942
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
5. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs.
Tarella C; Castellino C; Locatelli F; Caracciolo D; Corradini P; Falda M; Novarino A; Tassi V; Pileri A
Bone Marrow Transplant; 1998 Feb; 21(4):401-7. PubMed ID: 9509976
[TBL] [Abstract][Full Text] [Related]
6. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation.
de Azevedo AM; Nucci M; Maiolino A; Vigorito AC; Simões BP; Aranha FJ; Tabak DG; Voltarelli J; de Souza CA
Bone Marrow Transplant; 2002 May; 29(9):745-51. PubMed ID: 12040471
[TBL] [Abstract][Full Text] [Related]
7. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
8. Delayed introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: retrospective study of 45 cases.
Dolgopolov I; Andreeva L; Yankelevich M; Mscheidze D; Siegel S; Mentkevich G
Am J Hematol; 2003 Aug; 73(4):225-9. PubMed ID: 12879423
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
Ozcan M; Ustün C; Akçağlayan E; Akan H; Arslan O; Ilhan O; Beksaç M; Gürman G; Demirer T; Arat M; Celebi H; Konuk N; Uysal A; Koç H
Bone Marrow Transplant; 2001 Mar; 27(5):499-505. PubMed ID: 11313683
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults.
Ojeda E; Garcia-Bustos J; Aguado M; Arrieta R; Quevedo E; Yuste VJ; Canales M; Hernandez-Navarro F
Bone Marrow Transplant; 1999 Sep; 24(6):601-7. PubMed ID: 10490724
[TBL] [Abstract][Full Text] [Related]
11. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial.
Bolwell BJ; Pohlman B; Andresen S; Kalaycio M; Goormastic M; Wise K; Wakeling A; Dannley R; Overmoyer B
Bone Marrow Transplant; 1998 Feb; 21(4):369-73. PubMed ID: 9509971
[TBL] [Abstract][Full Text] [Related]
12. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness.
Faucher C; le Corroller AG; Blaise D; Novakovitch G; Manonni P; Moatti JP; Maraninchi D
Bone Marrow Transplant; 1994 Dec; 14(6):895-901. PubMed ID: 7536070
[TBL] [Abstract][Full Text] [Related]
13. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.
Piccirillo N; Sica S; Laurenti L; Chiusolo P; La Barbera EO; Sorà F; Leone G
Bone Marrow Transplant; 1999 Jun; 23(12):1245-50. PubMed ID: 10414910
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
[TBL] [Abstract][Full Text] [Related]
15. Use of concurrent G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease.
Madero L; González-Vicent M; Molina J; Madero R; Quintero V; Díaz MA
Bone Marrow Transplant; 2000 Aug; 26(4):365-9. PubMed ID: 10982281
[TBL] [Abstract][Full Text] [Related]
16. [A clinical study of rhG-CSF in accelerating hematological recovery following autologous hematopoietic stem cells transplantation].
Yang JL; Shi YK; He XH; Zhou SY; Zhou AP; Han XH; Liu P; Zhang CG; Ai B
Ai Zheng; 2003 Aug; 22(8):785-9. PubMed ID: 12917020
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
18. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
[TBL] [Abstract][Full Text] [Related]
19. Effects of rhG-CSF (filgrastim) on the recovery of hematopoiesis after high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children: a report from the Children's Cancer and Leukemia Study Group of Japan.
Suzue T; Takaue Y; Watanabe A; Kawano Y; Watanabe T; Abe T; Kuroda Y; Matsushita T; Kikuta A; Iwai A
Exp Hematol; 1994 Nov; 22(12):1197-202. PubMed ID: 7523170
[TBL] [Abstract][Full Text] [Related]
20. Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation.
Colby C; McAfee SL; Finkelstein DM; Spitzer TR
Bone Marrow Transplant; 1998 May; 21(10):1005-10. PubMed ID: 9632273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
